Infectious Disease · PANCE / PANRE

HPV Genital Warts (Condyloma acuminatum)

Soft, exophytic anogenital warts caused by low-risk HPV types 6 and 11; high-risk types (16, 18) drive cervical, anal, oropharyngeal cancers — vaccination is highly effective.

Also known as: HPV, human papillomavirus, genital warts, condyloma acuminatum, venereal warts

Overview

Anogenital warts caused predominantly by HPV types 6 and 11 (low-risk for cancer). Distinct from oncogenic HPV types (16, 18 among others) responsible for cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers.

Epidemiology

HPV is the most common STI in the US — most sexually active adults will be infected. Genital warts affect ~1% of sexually active adults at any time. HPV-attributable cancers cause ~36,000 US cases yearly. HPV vaccine (now 9-valent covering types 6/11/16/18/31/33/45/52/58) has dramatically reduced incidence in vaccinated cohorts.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full HPV Genital Warts (Condyloma acuminatum) outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in

Free to start · No credit card · Cancel anytime

Risk factors

Early age at first intercourse, multiple lifetime partners
Smoking (impairs clearance and accelerates progression)
Immunocompromise (HIV, transplant) — more extensive disease, higher recurrence
Other STIs
Lack of HPV vaccination

Pathophysiology

HPV is a non-enveloped DNA virus that infects basal keratinocytes through microabrasions. Low-risk types (6, 11) cause epithelial proliferation → warts. High-risk types (16, 18) integrate viral DNA, with E6 and E7 oncoproteins inactivating p53 and Rb → uncontrolled cell cycle progression and malignant transformation over years to decades.

Clinical presentation

Symptoms

Soft, flesh-colored, pink, or gray cauliflower-like (verrucous) papules on genital mucosa, perianal area, or proximal anal canal
Often asymptomatic; may cause pruritus, bleeding with friction, dyspareunia
Warts may coalesce into large plaques (Buschke-Lowenstein tumor in immunocompromised)
Oral/laryngeal lesions possible with oral-genital exposure
High-risk HPV usually asymptomatic until precancer or cancer develops — found on Pap/HPV screening

Signs / physical exam

Visible exophytic warts on external genitalia, vagina, cervix, urethra, perianal, anal canal
Cervical involvement may require colposcopy/biopsy
Acetowhitening (5% acetic acid applied to lesion) — historical adjunct; non-specific
Speculum exam for cervical/vaginal lesions

Classic findings

Soft, fleshy, cauliflower-shaped exophytic anogenital papules in a sexually active adult — condyloma acuminatum. Distinguish from flat moist condyloma lata of secondary syphilis.

Differential diagnosis

Condyloma lata (secondary syphilis) — Moist, flat, gray-white plaques in intertriginous areas; RPR positive
Molluscum contagiosum — Dome-shaped, umbilicated papules; poxvirus
Skin tags (acrochordon) — Pedunculated, smooth, soft; not infectious
Vestibular papillomatosis — Normal variant in women — symmetric, soft frond-like papillae of the vulvar vestibule
Pearly penile papules / Fordyce spots — Normal anatomic variants — rows of small dome-shaped papules at coronal sulcus / sebaceous glands
Bowenoid papulosis / Buschke-Lowenstein — HPV-related; biopsy if pigmented, ulcerated, or rapidly growing
Squamous cell carcinoma — Indurated, ulcerated, bleeding; biopsy any concerning lesion

Diagnostic workup

Diagnostic criteria

Clinical diagnosis for typical anogenital warts; histology for atypical lesions.

Labs

Clinical diagnosis for typical warts; biopsy only for atypical, pigmented, ulcerated, or recurrent lesions
Cervical cancer screening per ASCCP guidelines:
• Ages 21-29: cytology every 3 years
• Ages 30-65: HPV testing alone every 5 years (preferred) OR co-testing (Pap + HPV) every 5 years OR cytology alone every 3 years
• Discontinue at 65 if adequate prior screening and not high-risk
Anal Pap screening: HIV-positive MSM and other high-risk populations; ANCHOR trial supports treatment of HSIL
Test for concurrent STIs
HPV typing not used clinically for wart treatment

Imaging

Anoscopy / high-resolution anoscopy for anal canal lesions
Colposcopy for cervical abnormalities

Diagnostic algorithm

HPV Type Category	Examples	Major Diseases	Vaccine Coverage (Gardasil 9)
Low-risk	6, 11	Genital warts, RRP	Yes (6, 11)
High-risk	16, 18	70% of cervical cancers; anal, oropharyngeal CA	Yes (16, 18)
Other high-risk	31, 33, 45, 52, 58	Additional cervical and anogenital CA	Yes (all 5)

HPV type categories: clinical disease and 9-valent vaccine coverage.

Treatment

First-line

Patient-applied (self-administered):
• Imiquimod 3.75% or 5% cream — applied at bedtime several times/week up to 16 weeks; immune modulator
• Podofilox 0.5% solution/gel — applied BID × 3 days, 4 days off, up to 4 cycles
• Sinecatechins 15% ointment (green tea catechins) — TID up to 16 weeks
Provider-applied:
• Cryotherapy with liquid nitrogen — every 1-2 weeks until clearance
• Trichloroacetic acid (TCA) 80-90% — weekly application
• Surgical removal (excision, electrosurgery, laser ablation) for large or refractory lesions
Cervical and intra-anal lesions require specialty management
No therapy is uniformly effective; recurrence common; choice based on lesion size/location, patient preference, and cost

Second-line / adjunct

Combination or sequential therapy for refractory disease
Intralesional interferon — refractory cases
Cidofovir gel — experimental
HPV vaccine (Gardasil 9) — primary prevention, NOT treatment of existing infection (but recommended through age 26 universally and through age 45 with shared decision-making per ACIP)

Complications

Recurrence (common with all therapies)
Psychosocial distress, sexual dysfunction
Progression of high-risk HPV to cervical, anal, vulvar, vaginal, penile, or oropharyngeal cancer
Buschke-Lowenstein giant condyloma (locally destructive)
Recurrent respiratory papillomatosis in infants of mothers with active genital HPV at delivery (rare)

PANCE pearls

HPV vaccine recommended routinely for ages 9-12 (start as early as 9), catch-up to age 26, and shared decision-making 27-45 (ACIP 2019).
Vaccine prevents but does not treat existing infection — vaccinate before sexual debut for maximal benefit.
Cervical screening guidelines (ASCCP/USPSTF): primary HPV testing every 5 years (ages 30-65) is now the preferred strategy.
Wart treatments are destructive, not curative — recurrence often reflects residual subclinical infection.
Genital warts caused by low-risk types (6, 11) do not progress to cancer — but high-risk coinfection is common; screen the cervix appropriately.

References

CDC 2021 — Sexually Transmitted Infections Treatment Guidelines, 2021 (MMWR Recommendations and Reports)
ACIP 2019 — Meites et al., Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices (MMWR)
ASCCP 2019 — Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors

Practice Infectious Disease questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.